AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04672447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
Study NCT04672447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
Study NCT01288950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
Study NCT01907503 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Evaluation of the balance of force platform
Study NCT03785951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Protein with Leucine
Description: Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.
Study NCT00554099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: 6 - 400 mg tablets once daily
Study NCT00554099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
Study NCT00554099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
Study NCT00554099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary advice
Study NCT00554099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Advice
Description: Dietary advice
Study NCT00554099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic for Diverticulitis
Description: Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
Study NCT00554099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic for Diverticulitis
Description: Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
Study NCT01864447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)
Study NCT04972084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerscope group
Description: Treatment of Class II malocclusions using Powerscope appliance
Study NCT00480259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hyperproteic nutrition
Study NCT00480259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hyperproteic nutrition
Study NCT01754194 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric Sleeve Resection
Description: Laparoscopic Gastric Sleeve Resection
Study NCT00876954 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normothermia
Description: Warming without increase in core temperature
Study NCT00876954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermia
Description: Core hyperthermia (39 °C) for 2,5 hours
Study NCT01754194 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: Laparoscopic Roux-en-Y Gastric Bypass
Study NCT02122809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Take orally
Study NCT03356509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will be performed on a stationary bicycle ergometer.
Study NCT03924999 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined decongestive treatment (CDT) & Combined exercise
Description: Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.
Study NCT03924999 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression & Combined exercise
Description: Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
Study NCT03924999 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise
Description: 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
Study NCT02042313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural infusion
Study NCT02042313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined paravertebral infusion and single shot of TAP block
Study NCT02238015 — intervention group
Intervention type: PROCEDURE
Intervention: cataract surgery
Description: All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
Study NCT02961049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective enamel etched
Description: Selective enamel etched with 35% phosphoric acid for 15 seconds.
Study NCT01916850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 400 mg
Study NCT01916850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 800 mg
Study NCT01916850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 Placebo
Study NCT00707746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Study NCT00707746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05204056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iced normal saline
Description: Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy
Study NCT05204056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: 20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
Study NCT02961049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wash and dry
Description: Wash and dry with absorbent paper.
Study NCT05204056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
Study NCT05204056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion
Description: Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
Study NCT02392403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus CI532 cochlear implant
Study NCT03758690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Electromagnetic (HIFEM) Field Device
Description: The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
Study NCT03308045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pEYS606
Description: pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
Study NCT00586443 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bevacizumab, everolimus, panitumumab
Description: Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15.
Study NCT02603445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCL201
Study NCT02603445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Study NCT02675335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT02675335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03218553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
Study NCT03218553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
Study NCT03149003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888 Dosing Emulsion
Description: DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
Study NCT03149003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
Study NCT03149003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
Study NCT00967161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty
Study NCT00967161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty
Study NCT00967161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motion analysis
Description: Motion analysis (Gait/EMG during walking and functional tasks)
Study NCT00967161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motion analysis
Description: Motion analysis (Gait/EMG during walking and functional tasks)
Study NCT04363047 — intervention group
Intervention type: OTHER
Intervention: 40ml blood sample
Description: We'll be collecting cells, DNA and serum.
Study NCT00281190 — intervention group
Intervention type: PROCEDURE
Intervention: Blood drawing
Description: blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
Study NCT03060239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy
Description: Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
Study NCT03084029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 international units
Study NCT00281190 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage during indicated bronchoscopy
Description: A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
Study NCT02961049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total-etch adhesive system
Description: Two layers of pirmer/bond on enamel and dentin with a brush.
Study NCT03084029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 international units
Study NCT02961049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: self-conditioning adhesive system
Description: One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
Study NCT02188498 — intervention group
Intervention type: PROCEDURE
Intervention: Polysomnography
Description: Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
Study NCT02804308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Training
Study NCT00364533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR (CG5503)
Description: Fixed Dose 50, 75, \& 100 mg BID for 3 days
Study NCT00364533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fixed Dose Matching placebo for 3 days
Study NCT00364533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCL IR
Description: Fixed Dose 10 mg BID for 3 days
Study NCT00364533 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tapentadol IR (CG5503)
Description: Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
Study NCT00254540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248 capsule
Description: 50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
Study NCT05633524 — intervention group
Intervention type: OTHER
Intervention: blood sample analysis
Description: All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
Study NCT04533308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation in virtual reality
Description: Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality
Study NCT00319917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study NCT01702740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg/kg CNTO 136
Description: Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study NCT01702740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg/kg CNTO 136
Description: Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study NCT00319917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT01714154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg orally every 12 hours
Study NCT01714154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg orally every 12 hours
Study NCT01714154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrobuvir
Description: 200 mg orally every 12 hours
Study NCT02989740 — intervention group
Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography
Description: Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
Study NCT00082355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase (Activase, Genentech)
Description: Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
Study NCT04371887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Tailoring
Description: The guided local tailoring approach will employ a standard structured process, including (1) convening a project team, (2) conducting a local diagnostic process to identify likely barriers using provider/patient survey and interviews with providers/administrators, (3) selecting from a pre-developed menu of implementation strategies categorized by core function (form and function menu), and (4) deploying the selected strategies in collaboration with local implementation and improvement consultants.
Study NCT02940847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique
Description: It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
Study NCT02940847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique
Description: Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
Study NCT01572233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Physical Activity and Psycho-Education (PPAPE) Program
Description: 1. Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~2. The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment.
Study NCT03590054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV on day 1 of every 21 day cycle
Study NCT00799825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's HPV vaccine GSK580299 (Cervarix™)
Description: All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
Study NCT03916757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-Boost
Description: Open label setting
Study NCT01702740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg CNTO 136
Description: Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study NCT00995683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half molar sodium lactate
Description: intravenous infusion of 0.5 ml/kg during 48 hours
Study NCT00995683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic sodium chloride
Description: intravenous infusion of 0.5 ml/kg during 48 hours
Study NCT03146845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLEVYN Life Non-Bordered
Description: Foam Dressing
Study NCT01053364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NL-Prow interspinous spacer implant
Description: Interspinous spacer implant
Study NCT01254227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox and Deferoxamine
Study NCT04146025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Coach Intervention
Description: 1. Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~2. Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~3. Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach.
Study NCT03585179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tranexamic Acid
Description: Participants will take a pill of 250 mg bid for 12 weeks
Study NCT03585179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% topical tranexamic acid
Description: Participants will apply a layer of gel on the affected skin bid for 12 weeks
Study NCT03585179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% hydroquinone
Description: Participants will apply a layer of cream on the affected skin once at night
Study NCT00824044 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
Study NCT03092973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Study NCT01702740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study NCT01328340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-speed power training
Description: exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
Study NCT01328340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow-speed strength training
Description: exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
Study NCT02145871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard fluid management